Yahoo Finance

Operations: Kelun-Biotech generates revenue primarily from its pharmaceuticals segment, amounting to CN¥1.88 billion. The company focuses on developing and commercializing novel drugs for unmet medical needs both in China and internationally.

Sichuan Kelun-Biotech Biopharmaceutical has shown promising growth, with revenue increasing by 24.7% over the past year and expected to grow at an annual rate of 25.2%. The company’s R&D expenses are significant, reflecting a strong focus on innovation, with CNY 1 billion invested in the past year alone. Recent product announcements include positive results for their anti-TROP2 ADC sacituzumab tirumotecan (sac-TMT) in various cancer treatments, indicating robust potential for future expansion and market penetration.

• Get an in-depth perspective on Sichuan Kelun-Biotech Biopharmaceutical's performance by reading our health report here.

• Learn about Sichuan Kelun-Biotech Biopharmaceutical's historical performance.

Akeso

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc. is a biopharmaceutical company that researches, develops, manufactures, and commercializes antibody drugs with a market cap of HK$48.31 billion.

Operations: Akeso focuses on the research, development, production, and sale of biopharmaceutical products, generating CN¥1.87 billion in revenue. The company specializes in antibody drugs within the biopharmaceutical sector.

Akeso's revenue is forecast to grow 32.7% annually, significantly outpacing the Hong Kong market's 7.3%. Despite a net loss of CNY 238.59 million for H1 2024, its innovative R&D efforts are noteworthy, with substantial investment in developing ivonescimab and other bi-specific antibodies. Ivonescimab recently received priority review for new indications and demonstrated superior efficacy in clinical trials compared to pembrolizumab, positioning Akeso as a potential leader in immunotherapy advancements.

• Click here and access our complete health analysis report to understand the dynamics of Akeso.

• Evaluate Akeso's historical performance by accessing our past performance report.

Where To Now?

• Access the full spectrum of 45 SEHK High Growth Tech and AI Stocks by clicking on this link.

• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.

• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SEHK:3888 SEHK:6990 and SEHK:9926.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com